Carcinosarcoma

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This Phase 3 trial is testing a new drug called puxitatug samrotecan against standard chemotherapy in 800 people with advanced endometrial cancer that has worsened after platinum-based chemo and immunotherapy. The goal is to see if the new drug can delay cancer growth or improve …

This study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…

This phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to se…

This study tests a new device that delivers a special type of radiation directly into skin tumors. The goal is to see if it can shrink or control the cancer. The study is for adults with certain types of skin cancer, including squamous cell carcinoma and basal cell carcinoma. Par…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose …

This phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…

This study tests whether a less invasive lymph node procedure (sentinel mapping) can lower the risk of long-term leg swelling compared to standard lymph node removal. About 428 women with stage I endometrial cancer will be followed for 18 months after hysterectomy. The goal is to…

This study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features…

This Swiss study is testing whether creating a detailed molecular profile of each patient's tumor can help doctors choose more effective treatments for advanced ovarian cancer. Sixty newly diagnosed patients will be randomly assigned to either standard care or a personalized trea…

This study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This registry is collecting information from up to 9,000 people in Germany with sarcoma or carcinosarcoma. Researchers will track how often different subtypes occur, how they progress, and what treatments patients receive. The goal is to better understand these rare cancers and i…